ClinicalTrials.gg
CompletedNCT02076009Updated May 1, 2025Results posted

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

A Phase 3 interventional study of Daratumumab and Lenalidomide in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Completed at 146 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-01.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
569
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 132 studies testing daratumumab in Multiple Myeloma — 21 open to participants now, 63 under way, 10 of them phase 3. daratumumab · Multiple Myeloma.

Enrollment
9th of 132
569 · median 50
Started
2014
with 3 others
Phase 3
24 of 132
4 open now
Registered
3rd of 132
by date
Lead sponsor
17 of 132
Janssen Research & Development, LLC

Among the 132 studies testing daratumumab in Multiple Myeloma, this one is the 9th largest by enrollment, is one of 4 that started in 2014, is one of 24 in phase 3, and was the 3rd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

21 of the 132 studies testing daratumumab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About daratumumab

daratumumab: first FDA approval 2015 (DARZALEX), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing daratumumab in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple myeloma.

Read the detailed description

This is a randomized (participants will be assigned by chance to study treatments), open-label (all participants and study personnel will know the identity of the study treatments), active-controlled (none of the study treatments are placebo), parallel-group (both treatment arms will run at the same time), multicenter study. In this study, daratumumab, lenalidomide, and low-dose dexamethasone (DRd) will be compared with lenalidomide and low dose dexamethasone (Rd) in participants with relapsed or refractory multiple myeloma. Participants will be randomized in a 1:1 ratio to receive either DRd or Rd. The study will include a Screening Phase, a Treatment Phase (involving treatment cycles of approximately 28 days in length), and a Follow-up Phase. The Treatment Phase will extend from the administration of the first dose of study medication until disease progression or unacceptable toxicity. Participants will also discontinue study treatment if: they become pregnant; have their dose held for more than 28 days (or if 3 consecutive planned doses of daratumumab are missed for reasons other than toxicity); or for safety reasons (for example, adverse event). The Follow-up Phase will begin at the end of treatment and will continue until death, loss to follow-up, consent withdrawal for study participation, or the final overall survival (OS) analysis, whichever occurs first. Eligible participants from Rd group who have had sponsor confirmed disease progression will be offered the option for treatment with daratumumab monotherapy (of 28 days cycle). The primary endpoint will be progression-free survival (PFS). Analysis of the primary endpoint was performed at a pre-specified point determined by PFS events with a clinical cutoff of March 7, 2016 when 169 events of death or progression had occurred. The end of study is anticipated at approximately 6 years after the last participant is randomized. Blood and urine samples will be obtained at time points during the study, together with bone marrow aspirates/biopsies and skeletal surveys. Participant safety will be assessed throughout the study.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
  • Daratumumab
  • Lenalidomide
  • Dexamethasone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have documented multiple myeloma and
  • Must have received at least 1 for multiple myeloma and achieved a response (partial response or better) to at least one prior regimen
  • Must have documented evidence of progressive disease as defined by the International Myeloma Working Group criteria on or after their last regimen
  • Must have an Performance Status score of 0, 1, or 2
  • If a participant has received subsequent anticancer therapy (salvage therapy), the participant must have a "" defined as 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is longer, before the planned start date of daratumumab monotherapy. The only exception is the emergency use of a short course of (equivalent of dexamethasone 40 milligram per day for a maximum of 4 days) before Daratumumab monotherapy

Exclusion criteria

Exclusion Criteria:

  • Has received any of the following therapies: daratumumab or other anti-CD38 therapies
  • Has received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of the treatment
  • Disease shows evidence of refractoriness or intolerance to lenalidomide or if previously treated with a lenalidomide-containing regimen the participant is excluded if he or she discontinued due to any adverse event related to prior lenalidomide treatment
  • Has received stem cell transplantation within 12 weeks before the date of randomization, or previously received an allogenic stem cell transplant (regardless of timing), or planning to undergo a stem cell transplant prior to progression of disease
  • History of (other than multiple myeloma) within 5 years before the first dose of daratumumab monotherapy (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or breast, or other non-invasive lesion, that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 5 years)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
569 participants (actual)

Study arms

  • Experimental
    Daratumumab + lenalidomide + dexamethasone

    During each 28-day treatment cycle, participants will receive daratumumab, lenalidomide, and dexamethasone.

    Drug: Daratumumab · Drug: Lenalidomide · Drug: Dexamethasone

  • Active comparator
    Lenalidomide + dexamethasone

    During each 28-day treatment cycle, participants will receive lenalidomide and dexamethasone.

    Drug: Lenalidomide · Drug: Dexamethasone

Interventions

  • Daratumumab 16mg/kg will be administered as an intravenous (IV) infusion (into the vein) as per the following schedule: once a week during treatment cycles 1 and 2; every 2 weeks during treatment cycles 3 to 6; and every 4 weeks for cycles 7 and onwards. Following amendment 8, participants receiving daratumumab IV have the option to switch to daratumumab subcutaneous (SC) 1800 mg/dose until documented progression, unacceptable toxicity, or the end of study on Day 1 of any cycle, at the discretion of the investigator.

  • Lenalidomide will be administered at a dose of 25 mg orally (by mouth) on Days 1 through 21 of each treatment cycle.

  • Dexamethasone (or equivalent in accordance with local standards) will be administered as a total dose of 40 mg weekly (or 20 mg weekly for participants \> 75 years old or with a body mass index \< 18.5).

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    PFS: duration from date of randomization to either progressive disease (PD)/death, whichever occurred first. PD: defined as meeting any 1 of following criteria: Increase of greater than equal to (\>=)25 percent(%) in level of serum M-protein from lowest response value and absolute increase must be \>=0.5 gram per deciliter (g/dL); Increase of \>=25% in 24-hours(h) urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be \>=200 mg/24h; Only in participants without measurable serum and urine M-protein levels: increase of \>=25% in difference between involved and uninvolved free light chain (FLC) levels from lowest response value and absolute increase must be \>10 mg/dL; Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) attributed solely to plasma cell (PC) proliferative disorder.

    Time frame: From randomization to either disease progression or death whichever occurs first (up to 21 months)

Secondary outcomes

  1. Time to Disease Progression (TTP)

    TTP was defined as time from date of randomization to date of first documented evidence of progressive disease (PD). PD was defined as meeting any one of following criteria: Increase of \>=25% in level of serum M-protein from lowest response value and absolute increase must be \>=0.5 g/dL; Increase of \>=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be \>=200 mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of \>=25% in difference between involved and uninvolved free light chain (FLC) levels from lowest response value and absolute increase must be \>10 milligram per deciliter (mg/dL); Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to plasma cell (PC) proliferative disorder.

    Time frame: From randomization to disease progression (up to 21 months)

  2. Percentage of Participants Who Achieved Very Good Partial Response (VGPR) or Better

    VGPR or better is defined as the percentage of participants who achieved VGPR, complete response (CR) and stringent complete response (sCR) according to the International Myeloma Working Group criteria (IMWG). IMWG criteria for VGPR: Serum and urine M-component detectable by immunofixation but not on electrophoresis, or \>=90% reduction in serum M-protein plus urine M-protein \<100 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of \>90% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. In addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required; CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% PCs in bone marrow; sCR: CR and normal FLC ratio, absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4 color flow cytometry.

    Time frame: From randomization to disease progression (up to 21 months)

  3. Percentage of Participants With Negative Minimal Residual Disease (MRD)

    Minimal residual disease was assessed for all participants who achieved a complete response (CR) or stringent complete response (sCR). CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% PCs in bone marrow; sCR: CR and normal FLC ratio, absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4 color flow cytometry. The MRD negativity rate was defined as the percentage of participants who had negative MRD assessment at any time point after the first dose of study drugs by evaluation of bone marrow aspirates or whole blood at 10\^ minus (-) 4, 10\^-5, 10\^-6 threshold.

    Time frame: From randomization to the date of first documented evidence of PD (up to 87.5 months)

  4. Overall Response Rate

    Overall response rate was defined as the percentage of participants who achieved a partial response (PR) or better according to the International Myeloma Working Group (IMWG) criteria, during or after study treatment. IMWG criteria for PR: \>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria, in addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required.

    Time frame: From randomization to disease progression (up to 21 months)

  5. Overall Survival (OS)

    Overall survival was measured from the date of randomization to the date of the participant's death.

    Time frame: From randomization to date of death due to any cause (up to 87.5 months)

  6. Time to Response

    Time to response was defined as the time between the date of randomization and the first efficacy evaluation that the participant met all criteria for partial response (PR) or better.

    Time frame: From randomization up to first documented CR or PR (up to 21 months)

  7. Duration of Response (DOR)

    DOR was defined for participants with confirmed response (PR or better) as time between first documentation of response and disease progression/death due to PD, whichever occurs first. PD was defined as meeting any one of following criteria: Increase of \>=25% in level of serum M-protein from lowest response value and absolute increase must be \>=0.5g/dL; Increase of \>=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be \>=200mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of \>=25% in difference between involved and uninvolved FLC levels from lowest response value and absolute increase must be \>10mg/dL; Definite increase in size of existing bone lesions/soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5mg/dL) that can be attributed solely to PC proliferative disorder.

    Time frame: From randomization to the date of first documented evidence of PD (up to 21 months)

  8. Time to Subsequent Anticancer Treatment

    Time to subsequent anticancer treatment was defined as the time from randomization to the start of subsequent anticancer treatment or death due to progressive disease (PD), whichever occurs first.

    Time frame: From randomization to date of start of subsequent anticancer treatment or death due to PD, whichever occured first (up to 87.5 months)

07

Results

Posted Feb 10, 2017

Participant flow

Participant flow — Overall Study
MilestoneLenalidomide, Low-dose Dexamethasone (Rd)Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)
Started283286
Treated (safety population)281283
Completed00
Not completed283286
Withdrew: Death172153
Withdrew: Withdrawal by subject1612
Withdrew: Lost to follow-up42
Withdrew: Progressive disease10
Withdrew: Physician decision01
Withdrew: End of data collection90118

Outcome measures

PrimaryProgression-free Survival (PFS)

PFS: duration from date of randomization to either progressive disease (PD)/death, whichever occurred first. PD: defined as meeting any 1 of following criteria: Increase of greater than equal to (\>=)25 percent(%) in level of serum M-protein from lowest response value and absolute increase must be \>=0.5 gram per deciliter (g/dL); Increase of \>=25% in 24-hours(h) urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be \>=200 mg/24h; Only in participants without measurable serum and urine M-protein levels: increase of \>=25% in difference between involved and uninvolved free light chain (FLC) levels from lowest response value and absolute increase must be \>10 mg/dL; Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) attributed solely to plasma cell (PC) proliferative disorder.

Time frame:
From randomization to either disease progression or death whichever occurs first (up to 21 months)
Reported as:
Median · months
Progression-free Survival (PFS)
monthsLenalidomide, Low-dose Dexamethasone (Rd)Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)
Progression-free Survival (PFS)18.43 (13.86 to NA)NA (NA to NA)
SecondaryTime to Disease Progression (TTP)

TTP was defined as time from date of randomization to date of first documented evidence of progressive disease (PD). PD was defined as meeting any one of following criteria: Increase of \>=25% in level of serum M-protein from lowest response value and absolute increase must be \>=0.5 g/dL; Increase of \>=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be \>=200 mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of \>=25% in difference between involved and uninvolved free light chain (FLC) levels from lowest response value and absolute increase must be \>10 milligram per deciliter (mg/dL); Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to plasma cell (PC) proliferative disorder.

Time frame:
From randomization to disease progression (up to 21 months)
Reported as:
Median · months
Time to Disease Progression (TTP)
monthsLenalidomide, Low-dose Dexamethasone (Rd)Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)
Time to Disease Progression (TTP)18.43 (14.78 to NA)NA (NA to NA)
SecondaryPercentage of Participants Who Achieved Very Good Partial Response (VGPR) or Better

VGPR or better is defined as the percentage of participants who achieved VGPR, complete response (CR) and stringent complete response (sCR) according to the International Myeloma Working Group criteria (IMWG). IMWG criteria for VGPR: Serum and urine M-component detectable by immunofixation but not on electrophoresis, or \>=90% reduction in serum M-protein plus urine M-protein \<100 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of \>90% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. In addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required; CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% PCs in bone marrow; sCR: CR and normal FLC ratio, absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4 color flow cytometry.

Time frame:
From randomization to disease progression (up to 21 months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Very Good Partial Response (VGPR) or Better
percentage of participantsLenalidomide, Low-dose Dexamethasone (Rd)Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)
Percentage of Participants Who Achieved Very Good Partial Response (VGPR) or Better44.2 (38.3 to 50.3)75.8 (70.4 to 80.7)
SecondaryPercentage of Participants With Negative Minimal Residual Disease (MRD)

Minimal residual disease was assessed for all participants who achieved a complete response (CR) or stringent complete response (sCR). CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% PCs in bone marrow; sCR: CR and normal FLC ratio, absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4 color flow cytometry. The MRD negativity rate was defined as the percentage of participants who had negative MRD assessment at any time point after the first dose of study drugs by evaluation of bone marrow aspirates or whole blood at 10\^ minus (-) 4, 10\^-5, 10\^-6 threshold.

Time frame:
From randomization to the date of first documented evidence of PD (up to 87.5 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Negative Minimal Residual Disease (MRD)
percentage of participantsLenalidomide, Low-dose Dexamethasone (Rd)Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)
MRD negative rate (10^-4)10.2 (7.0 to 14.4)40.6 (34.8 to 46.5)
MRD negative rate (10^-5)6.7 (4.1 to 10.3)33.2 (27.8 to 39.0)
MRD negative rate (10^-6)1.8 (0.6 to 4.1)13.3 (9.6 to 17.8)
SecondaryOverall Response Rate

Overall response rate was defined as the percentage of participants who achieved a partial response (PR) or better according to the International Myeloma Working Group (IMWG) criteria, during or after study treatment. IMWG criteria for PR: \>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria, in addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required.

Time frame:
From randomization to disease progression (up to 21 months)
Reported as:
Number · percentage of participants
Overall Response Rate
percentage of participantsLenalidomide, Low-dose Dexamethasone (Rd)Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)
Overall Response Rate76.492.9
SecondaryOverall Survival (OS)

Overall survival was measured from the date of randomization to the date of the participant's death.

Time frame:
From randomization to date of death due to any cause (up to 87.5 months)
Reported as:
Median · months
Overall Survival (OS)
monthsLenalidomide, Low-dose Dexamethasone (Rd)Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)
Overall Survival (OS)51.84 (43.99 to 60.02)67.58 (53.13 to 80.53)
SecondaryTime to Response

Time to response was defined as the time between the date of randomization and the first efficacy evaluation that the participant met all criteria for partial response (PR) or better.

Time frame:
From randomization up to first documented CR or PR (up to 21 months)
Reported as:
Median · months
Time to Response
monthsLenalidomide, Low-dose Dexamethasone (Rd)Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)
Time to Response1.3 (1.1 to 1.9)1.0 (1.0 to 1.1)
SecondaryDuration of Response (DOR)

DOR was defined for participants with confirmed response (PR or better) as time between first documentation of response and disease progression/death due to PD, whichever occurs first. PD was defined as meeting any one of following criteria: Increase of \>=25% in level of serum M-protein from lowest response value and absolute increase must be \>=0.5g/dL; Increase of \>=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be \>=200mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of \>=25% in difference between involved and uninvolved FLC levels from lowest response value and absolute increase must be \>10mg/dL; Definite increase in size of existing bone lesions/soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5mg/dL) that can be attributed solely to PC proliferative disorder.

Time frame:
From randomization to the date of first documented evidence of PD (up to 21 months)
Reported as:
Median · months
Duration of Response (DOR)
monthsLenalidomide, Low-dose Dexamethasone (Rd)Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)
Duration of Response (DOR)17.4 (17.4 to NA)NA (NA to NA)
SecondaryTime to Subsequent Anticancer Treatment

Time to subsequent anticancer treatment was defined as the time from randomization to the start of subsequent anticancer treatment or death due to progressive disease (PD), whichever occurs first.

Time frame:
From randomization to date of start of subsequent anticancer treatment or death due to PD, whichever occured first (up to 87.5 months)
Reported as:
Median · months
Time to Subsequent Anticancer Treatment
monthsLenalidomide, Low-dose Dexamethasone (Rd)Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)
Time to Subsequent Anticancer Treatment23.1 (18.6 to 26.3)69.3 (49.7 to 82.8)

Adverse events

Collected over From randomization up to 30 days after last dose of study treatment (up to 87.5 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide, Low-dose Dexamethasone (Rd)—148/281 (52.7%)268/281 (95.4%)
Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)—205/283 (72.4%)278/283 (98.2%)
Most frequent serious events
Showing 10 of 350
Most frequent serious events
EventLenalidomide, Low-dose Dexamethasone (Rd)Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)
PneumoniaInfections and infestations32/28148/283
Lower respiratory tract infectionInfections and infestations3/28114/283
Febrile neutropeniaBlood and lymphatic system disorders4/28113/283
PyrexiaGeneral disorders5/28113/283
InfluenzaInfections and infestations7/28112/283
Pulmonary embolismRespiratory, thoracic and mediastinal disorders10/28112/283
Acute kidney injuryRenal and urinary disorders11/2818/283
BronchitisInfections and infestations7/28110/283
SepsisInfections and infestations8/2817/283
DiarrhoeaGastrointestinal disorders6/2818/283
Most frequent other events
Showing 10 of 84
Most frequent other events
EventLenalidomide, Low-dose Dexamethasone (Rd)Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)
NeutropeniaBlood and lymphatic system disorders136/281185/283
DiarrhoeaGastrointestinal disorders105/281169/283
Upper respiratory tract infectionInfections and infestations74/281123/283
FatigueGeneral disorders87/281119/283
AnaemiaBlood and lymphatic system disorders117/281118/283
CoughRespiratory, thoracic and mediastinal disorders43/281107/283
NasopharyngitisInfections and infestations62/281100/283
ConstipationGastrointestinal disorders77/28194/283
ThrombocytopeniaBlood and lymphatic system disorders90/28192/283
Muscle spasmsMusculoskeletal and connective tissue disorders61/28187/283

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lenalidomide, Low-dose Dexamethasone (Rd)Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)Total
Mean64.3 ± 8.8464.4 ± 9.0364.4 ± 8.93
Sex: Female, Male
Sex: Female, Male(Participants)Lenalidomide, Low-dose Dexamethasone (Rd)Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)Total
Female119113232
Male164173337
Region of Enrollment
Region of Enrollment(Participants)Lenalidomide, Low-dose Dexamethasone (Rd)Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)Total
Australia9918
Belgium101222
Canada171734
Denmark71017
France362157
Germany71118
Greece81119
Israel201939
Japan152136
Korea, Republic of202040
Netherlands314
Poland131528
Russian Federation301848
Spain252651
Sweden151631
Taiwan, Province of China91120
United Kingdom242751
United States152136
Stage of Disease (ISS)
Stage of Disease (ISS)(Participants)Lenalidomide, Low-dose Dexamethasone (Rd)Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)Total
I140137277
II8693179
III5756113
No. of Prior Lines of Therapy
No. of Prior Lines of Therapy(Participants)Lenalidomide, Low-dose Dexamethasone (Rd)Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)Total
1146149295
28085165
3383876
>3191433
08

Study locations

146 sites
  • Little Rock, Arkansas, United States
  • Gainesville, Florida, United States
  • West Palm Beach, Florida, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Iowa City, Iowa, United States
  • Louisville, Kentucky, United States
  • Baton Rouge, Louisiana, United States
  • New Orleans, Louisiana, United States
  • Bethesda, Maryland, United States
  • Columbia, Maryland, United States
  • Boston, Massachusetts, United States
  • Rochester, Minnesota, United States
  • Omaha, Nebraska, United States
  • New Brunswick, New Jersey, United States
  • New York, New York, United States
  • Charlotte, North Carolina, United States
  • Eugene, Oregon, United States
  • Spartanburg, South Carolina, United States
  • Austin, Texas, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • Fairfax, Virginia, United States
  • Camperdown, Australia
  • Geelong, Australia
  • Heidelberg, Australia
  • Malvern, Australia
  • South Brisbane, Australia
  • Southport, Australia
  • Anderlecht, Belgium
  • Antwerpen, Belgium
  • Edegem, Belgium
  • Gent, Belgium
  • Kortrijk, Belgium
  • Leuven, Belgium
  • Liege, Belgium
  • Calgary, Alberta, Canada
  • Edmonton, Alberta, Canada
  • Surrey, British Columbia, Canada
  • Vancouver, British Columbia, Canada
  • Halifax, Nova Scotia, Canada
  • Hamilton, Ontario, Canada
  • London, Ontario, Canada
  • Toronto, Ontario, Canada
  • Montreal, Quebec, Canada
  • Quebec City, Quebec, Canada
  • Copenhagen, Denmark
  • Odense, Denmark
  • Vejle, Denmark
  • Argenteuil, France
  • Caen, France
  • Lille, France
  • Limoges, France
  • Nantes Cedex 1, France
  • Paris, France
  • Pessac, France
  • Pierre Benite, France
  • Rennes, France
  • Toulouse Cedex 9, France
  • Tours Cedex 9, France
  • Vandoeuvre les Nancy, France
  • Berlin, Germany
  • Bonn, Germany
  • Hamburg, Germany
  • Hamm, Germany
  • Heidelberg, Germany
  • Jena, Germany
  • Karlsruhe, Germany
  • Koblenz, Germany
  • Köln, Germany
  • Saarbrücken, Germany
  • Villingen-Schwenningen, Germany
  • Athens Attica, Greece
  • Haifa, Israel
  • Jerusalem, Israel
  • Nahariya, Israel
  • Netanya, Israel
  • Petah Tikva, Israel
  • Ramat Gan, Israel
  • Tel Aviv, Israel
  • Hitachi, Japan
  • Kanazawa, Japan
  • Kobe, Japan
  • Kurume, Japan
  • Matsuyama, Japan
  • Nagoya, Japan
  • Narita, Japan
  • Ohgaki, Japan
  • Okayama, Japan
  • Osaka, Japan
  • Sendai-City, Japan
  • Shibukawa, Japan
  • Shibuya, Japan
  • Tachikawa, Japan
  • Tokyo, Japan
  • Gyeonggi-do, Korea, Republic of
  • Incheon, Korea, Republic of
  • Seoul, Korea, Republic of
  • Amsterdam, Netherlands
  • Rotterdam, Netherlands

Showing the first 100 of 146 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Cavo M, San-Miguel J, Usmani SZ, Weisel K, Dimopoulos MA, Avet-Loiseau H, Paiva B, Bahlis NJ, Plesner T, Hungria V, Moreau P, Mateos MV, Perrot A, Iida S, Facon T, Kumar S, van de Donk NWCJ, Sonneveld P, Spencer A, Krevvata M, Heuck C, Wang J, Ukropec J, Kobos R, Sun S, Qi M, Munshi N. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood. 2022 Feb 10;139(6):835-844. doi: 10.1182/blood.2021011101. PubMed 34289038 ↗
  • Plesner T, Dimopoulos MA, Oriol A, San-Miguel J, Bahlis NJ, Rabin N, Suzuki K, Yoon SS, Ben-Yehuda D, Cook G, Goldschmidt H, Grosicki S, Qin X, Fastenau J, Garvin W, Carson R, Renaud T, Gries KS. Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial. Br J Haematol. 2021 Jul;194(1):132-139. doi: 10.1111/bjh.17435. Epub 2021 Apr 6. PubMed 33822368 ↗
  • Avet-Loiseau H, San-Miguel J, Casneuf T, Iida S, Lonial S, Usmani SZ, Spencer A, Moreau P, Plesner T, Weisel K, Ukropec J, Chiu C, Trivedi S, Amin H, Krevvata M, Ramaswami P, Qin X, Qi M, Sun S, Qi M, Kobos R, Bahlis NJ. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. J Clin Oncol. 2021 Apr 1;39(10):1139-1149. doi: 10.1200/JCO.20.01814. Epub 2021 Jan 29. PubMed 33513030 ↗
  • Mateos MV, Spencer A, Nooka AK, Pour L, Weisel K, Cavo M, Laubach JP, Cook G, Iida S, Benboubker L, Usmani SZ, Yoon SS, Bahlis NJ, Chiu C, Ukropec J, Schecter JM, Qin X, O'Rourke L, Dimopoulos MA. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. Haematologica. 2020 Jan 31;105(2):468-477. doi: 10.3324/haematol.2019.217448. Print 2020. PubMed 31221782 ↗
  • Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751. PubMed 27705267 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2014 to primary completion in Mar 2016, 19 months.

Results were first posted in Feb 2017, 11 months after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 19 months is below that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2014
First posted
Mar 3, 2014
StartActual
Jul 23, 2014
Primary completionActual
Mar 7, 2016
CompletionActual
Nov 21, 2024
Results first posted
Feb 10, 2017
Last update
May 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02076009
Responsible party
Sponsor
First posted
Mar 3, 2014
Start date
Jul 23, 2014
Primary completion
Mar 7, 2016
Completion
Nov 21, 2024
Results posted
Feb 10, 2017
Last update
May 1, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daratumumab

Start the discussion